Aging.
Evidence-led reading on aging from the HL Benefits desk. Long reads, careful guides, and the boring-but-true positions the research keeps settling on.
Bryan Johnson's Peptide Stack — Decoded for Mortals on a Normal Budget
Bryan Johnson's public peptide story is narrower than the internet claims. Here's what is documented, what is speculation, and what to copy safely.
Photograph · HL BenefitsThe latest, in long form.
Browse all 20 →
Anti-Aging Peptides for Women Over 50: The Hormone-Friendly List
A conservative guide to anti-aging peptides after menopause, focused on skin support, GH-axis caution, HRT context, and monitoring.
Anti-Aging Peptides for Men Over 40: A Doctor's Honest Protocol
AgingThe 5 Peptides Tech Founders Are Stacking to Live Past 100
AgingThe BPC-157 + TB-500 "Wolverine Stack": Why Athletes Won't Train Without It
Epitalon: The Russian Longevity Peptide Linked to a 40% Lifespan Increase in Studies
Epitalon has intriguing longevity research, but the viral 40% lifespan claim is not cleanly supported by the fetched evidence.
SGLT2 Inhibitors for Longevity: The Diabetes Drug With Anti-Aging Potential
SGLT2 inhibitors extended mouse lifespan by 14% and cut human cardiovascular mortality by 38%. The science behind their anti-aging potential.
Rapamycin Side Effects and Safety: What Bryan Johnson's Experience Tells Us
A research-backed guide to rapamycin's side effects at anti-aging doses, from blood glucose changes to immune impacts, plus what Bryan Johnson's five-year experiment revealed.
We started this section because the conversation about aging had become unbearable — too loud, too certain, too often selling something. The boring middle — what the evidence actually supports, repeated across decades, written without a brand to defend — is not a position you can monetize, but it is the position the research keeps quietly settling on.
Companion sections.
All sections →Health
A companion section to aging, with its own evidence-led reading list.
Food & Nutrition
A companion section to aging, with its own evidence-led reading list.
Weight Loss
A companion section to aging, with its own evidence-led reading list.
Definitive guides.
All guides →
Peptide Therapy Beyond BPC-157: TB-500, GHK-Cu, and What's Legal in 2026
The FDA banned 19 peptides in 2023. Now RFK Jr. wants to reverse the ban. Here is what the research says about BPC-157, TB-500, and GHK-Cu.
Metabolic Drug Repurposing: SGLT2 Inhibitors, Acarbose, and Off-Label Anti-Aging
Two diabetes drugs are producing longevity data that rivals rapamycin. Here is what the research shows about SGLT2 inhibitors and acarbose for aging.
A claim about aging is not a study. A study is not a meta-analysis. A meta-analysis is not a guideline. The article doesn't fit on a label.
On our desk this week.
More from the desk →
Epigenetic Reprogramming: The Anti-Aging Therapy Entering Human Trials in 2026
The first human trial of epigenetic reprogramming has begun. ER-100 targets age-related eye disease using three Yamanaka factors to reverse cellular aging.
Bryan Johnson Blueprint Protocol: What the $2M/Year Anti-Aging Regimen Actually Involves
A detailed breakdown of Bryan Johnson's Blueprint protocol, separating evidence-backed interventions from expensive experiments.